AARD
NASDAQAardvark Therapeutics Inc.
News25/Ratings12
News · 26 weeks27+700%
2026-03-012026-08-23
Mix1190d
- SEC Filings6(55%)
- Insider4(36%)
- Other1(9%)
Latest news
25 items- INSIDERSEC Form 4 filed by Director Chi Jeffrey4 - Aardvark Therapeutics, Inc. (0001774857) (Issuer)
- INSIDERSEC Form 4 filed by Director Graf Susan E4 - Aardvark Therapeutics, Inc. (0001774857) (Issuer)
- INSIDERSEC Form 4 filed by Director Baynes Roy D.4 - Aardvark Therapeutics, Inc. (0001774857) (Issuer)
- INSIDERSEC Form 4 filed by Director Tong Victor Edward Jr4 - Aardvark Therapeutics, Inc. (0001774857) (Issuer)
- SECAardvark Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Aardvark Therapeutics, Inc. (0001774857) (Filer)
- SECSEC Form 10-Q filed by Aardvark Therapeutics Inc.10-Q - Aardvark Therapeutics, Inc. (0001774857) (Filer)
- SECAardvark Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Aardvark Therapeutics, Inc. (0001774857) (Filer)
- PRAardvark Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business UpdatesAssessing unblinded Phase 3 HERO and OLE data for ARD-101 in PWS in the third quarter of 2026 to support an informed determination of next steps Remains in active discussions with the FDA to support resolution of the clinical hold for ARD-101 program $73.9 million in cash, cash equivalents and short-term investments as of June 30, 2026, supports projected operations into late 2027 SAN DIEGO, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark or the Company) (NASDAQ:AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, today reported
- SECSEC Form DEF 14A filed by Aardvark Therapeutics Inc.DEF 14A - Aardvark Therapeutics, Inc. (0001774857) (Filer)
- SECSEC Form PRE 14A filed by Aardvark Therapeutics Inc.PRE 14A - Aardvark Therapeutics, Inc. (0001774857) (Filer)
- SECAardvark Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - Aardvark Therapeutics, Inc. (0001774857) (Filer)
- ANALYSTAardvark Therapeutics downgraded by Morgan Stanley with a new price targetMorgan Stanley downgraded Aardvark Therapeutics from Equal-Weight to Underweight and set a new price target of $3.00
- SECAardvark Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Aardvark Therapeutics, Inc. (0001774857) (Filer)
- PRAardvark Therapeutics Plans to Unblind HERO and OLE Data to Inform Path Forward Following FDA Clinical HoldSAN DIEGO, May 14, 2026 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark or the Company) (NASDAQ:AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, today announced that the U.S. Food and Drug Administration (FDA) has placed a full clinical hold on its investigational new drug application (IND) for ARD-101 related to the Company's previously announced voluntary pause. The clinical hold applies to all ongoing clinical studies under the IND, including the Phase 3 HERO trial (AVK-101-301) evaluating ARD-101 for the treatment of hyperphagia in patient
- SECSEC Form 10-Q filed by Aardvark Therapeutics Inc.10-Q - Aardvark Therapeutics, Inc. (0001774857) (Filer)
- SECAardvark Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Aardvark Therapeutics, Inc. (0001774857) (Filer)
- PRAardvark Therapeutics Reports First Quarter 2026 Financial Results and Provides Business UpdatesARD-101 and ARD-201 programs on voluntary pause; further guidance expected in Q2 2026 $91.2 million in cash, cash equivalents and short-term investments as of March 31, 2026, supports projected operations into mid-2027 SAN DIEGO, May 07, 2026 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark or the Company) (NASDAQ:AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, today reported financial results for the first quarter ended March 31, 2026, and provided pipeline and business updates. "We have been working closely with the FDA to comprehensively
- SECSEC Form EFFECT filed by Aardvark Therapeutics Inc.EFFECT - Aardvark Therapeutics, Inc. (0001774857) (Filer)
- SECSEC Form 424B5 filed by Aardvark Therapeutics Inc.424B5 - Aardvark Therapeutics, Inc. (0001774857) (Filer)
- SECSEC Form S-3 filed by Aardvark Therapeutics Inc.S-3 - Aardvark Therapeutics, Inc. (0001774857) (Filer)
- SECSEC Form 10-K filed by Aardvark Therapeutics Inc.10-K - Aardvark Therapeutics, Inc. (0001774857) (Filer)
- SECAardvark Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Aardvark Therapeutics, Inc. (0001774857) (Filer)
- PRAardvark Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdatesVoluntary pause of the Phase 3 HERO and OLE trials evaluating ARD-101 for the treatment of hyperphagia in individuals with Prader-Willi Syndrome, further guidance on the program expected in Q2 2026 ARD-201 obesity program, including POWER and STRENGTH trials, on voluntary pause pending next steps with ARD-101; further guidance on the program expected in Q2 2026 Clinical and preclinical data from ARD-101 program published in Molecular Metabolism $110.0 million in cash, cash equivalents and short-term investments as of December 31, 2025, supports projected operations into the second quarter of 2027 SAN DIEGO, March 23, 2026 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (NAS
- ANALYSTAardvark Therapeutics downgraded by Stifel with a new price targetStifel downgraded Aardvark Therapeutics from Buy to Hold and set a new price target of $6.00
- ANALYSTAardvark Therapeutics downgraded by Morgan Stanley with a new price targetMorgan Stanley downgraded Aardvark Therapeutics from Overweight to Equal-Weight and set a new price target of $7.00
AARD FAQ
6 questionsWhere does AARD stock trade?
Aardvark Therapeutics Inc. (AARD) is listed on NASDAQ.What sector and industry is AARD in?
Aardvark Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Aardvark Therapeutics Inc. go public?
Aardvark Therapeutics Inc. (AARD) completed its IPO in 2025.What are analysts saying about AARD?
Aardvark Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from Morgan Stanley: Underweight with a $300.00 price target on 2026-05-15.What companies are similar to AARD?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare AARD side-by-side with any of them on Quantisnow.How can I track AARD on Quantisnow?
Quantisnow aggregates Aardvark Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow AARD to receive live email and push alerts on every new disclosure.